← Back to all trials
Not Yet Recruiting
NCT07635485
VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML
Conditions: Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult)
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 50
Sponsor: The First Affiliated Hospital of Soochow University
Location: The First Affiliated Hospital of Soochow University Suzhou Jiangsu
Summary
The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine（VA) induction followed by bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hypoplastic and secondary acute myeloid leukemia (AML).
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years.
2. Previously untreated acute myeloid leukemia (AML) diagnosed according to the 2022 ELN guidelines. Patients with isolated extramedullary disease (i.e., no evidence of AML in bone marrow or peripheral blood) are not eligible.
3. Bone marrow biopsy demonstrating cellularity \
Source: ClinicalTrials.gov (NCT07635485). StuddyBuddy aggregates publicly available trial information.
